So should I continue to sell synthetic e-liquids for now? “In the coming weeks, we will continue to investigate companies that may be illegally marketing, selling, or distributing nicotine products other than tobacco, and take action if necessary,” said Brian King, director of the FDA`s Tobacco Products Center (CTP), who joined the agency less than two weeks ago. Many vape brands benefit from misconceptions among young people that synthetic nicotine is a safe alternative to nicotine from tobacco. All unauthorized synthetic nicotine products are now illegal. The FDA`s failure to fully enforce the law and remove these products from the market is unacceptable. It ignors explicit deadlines set by Congress and puts America`s children at risk.t.co/DhWFyH87HT While the FDA is reviewing thousands of applications from e-cigarette manufacturers to determine whether their products can remain on the market, brands that claim to use synthetic nicotine, including Puff Bar, have circumvented that review process. According to Stanford researchers, some brands even returned to the market with claims about synthetic formulations after the FDA rejected their applications for tobacco-derived nicotine products and ordered them to stop selling these products. The bill will go into effect 30 days after Biden is signed, which is expected to happen early next week. Manufacturers will then have an additional 30 days to submit pre-market tobacco applications (PMTAs) for synthetic products already on the market. Those who submit applications must obtain FDA approval within 60 days or remove these products from the market (or be subject to application). Many of the 200 manufacturers seeking approval of synthetic products through the PMTA route are members of the American Vapor Manufacturers Association (AVM), which primarily represents small businesses that manufacture and sell e-liquids.
In June, AVM filed an FDA citizen petition urging the agency to extend formal discretion to manufacturers who submitted applications before the deadline and complied with FDA rules and local laws. As we explained earlier this week, a bipartisan group of MPs and senators representing the interests of anti-vaping groups and the tobacco industry inserted bipartisan language from the House and Senate into the bill. Juul Labs and R.J. Reynolds actively lobbied for the law, saying it closed a “loophole” that allowed bad actors to “target teens” and evade FDA regulation. The FDA is engaged in the work necessary to take enforcement action as quickly as possible. If companies are found to be illegally marketing nicotine products other than tobacco, the agency typically first issues warning letters to voluntarily comply and takes enforcement action if necessary, including civil fines, tobacco bans, seizures or injunctions. In addition, any unauthorized nicotine product other than tobacco discovered for importation into the United States may be refused or denied approval. The shortened deadline imposed on manufacturers by Congress (and enforced by the FDA) may well be grounds for legal challenges to future FDA rejection orders.
The FDA is certainly aware of this, and despite the pressure it faces from anti-vaping groups and hardline politicians, the agency is unlikely to issue hundreds of thousands of standard rejections as it did in 2021. In addition, the FDA announced today that it has sent 107 warning letters to retailers in the past two weeks for selling illegal nicotine products, including certain e-cigarettes or electronic products, to underage buyers. The law clarifies that tobacco products, including nicotine products other than tobacco, cannot be legally sold to customers under the age of 21 after the new law is passed. The real reason Reynolds and Juul supported the bill (and state-level bills banning synthetic nicotine and creating registries for FDA-approved products) is to protect their profits. Disposable products sold by manufacturers such as Bad Boys Puff Bar synthetic nicotine are major competitors for Juul Labs and Reynolds` Vuse brand. And open-system products sold in vape stores and online continue to account for a large portion of the vaping market aus.@US_FDA have sounded the alarm about the threat synthetic nicotine vaporization poses to American children. So I led a bipartisan effort to close that gap and provide the FDA with tools to protect public health. But the deadline today is to remove unauthorized e-cigs from the market. Synthetic nicotine is the industry`s attempt to circumvent FDA oversight of lab-made nicotine that is not derived from tobacco and therefore did not fall under the agency`s jurisdiction. But the nationwide spending package passed in March makes clear that the FDA can regulate nicotine-containing tobacco products from any source,” the agency said in April, just before the law went into effect. A July 8 STAT News article described anti-vaping groups as “apoplectic” because the FDA had not taken action against companies that sold synthetics without filing a PMTA.
Durbin said he would investigate the agency. The FDA noted in its press release that after July 13, “any new nicotine product other than tobacco that has not received pre-market approval from the FDA cannot be legally marketed.” However, the Agency did not specify whether synthetic products would be a priority target for enforcement. Senator Durbin kept piling up. In his July 12 letter to FDA Commissioner Califf, also signed by Republican Senator Susan Collins of Maine, Durbin rebuked the agency for its past failures to eradicate vaping, saying the FDA “appears to be poised to once again protect our nation`s children from the dangers of nicotine addiction.” The bill was never presented at a committee hearing and was never debated or voted on, but its wording became the basis for the amendment inserted into the March spending bill that became law. Interestingly, the synthetic nicotine law was backed by Juul Labs and Vuse manufacturer RJ Reynolds, the makers of the country`s two most popular vaping products. The main competitors of Juul and Vuse? Eye-catching disposable products are also sold in traditional convenience stores and gas stations. Many e-cigarette manufacturers who have used tobacco-derived nicotine have recently switched to synthetic nicotine to avoid Food and Drug Administration (FDA) regulation. For example, Puff Bar, the top vape brand among teens, was ordered by the FDA in July 2020 to stop selling its tobacco-flavored e-cigarette products. In March 2021, the company returned to the market with synthetic “tobacco-free nicotine.” Congress has taken decisive action to end this addiction crisis among young people by authorizing the FDA to regulate synthetic nicotine products. The FDA has an obligation and responsibility to enforce the law.
As teen vaping continues at epidemic levels, synthetic nicotine threatens to exacerbate the teen nicotine use crisis. Here are some important things you should know about synthetic nicotine and how companies use it to evade federal child protection oversight. There are a variety of legal strategies that manufacturers will use in the coming weeks to challenge the synthetic law – and many still have pending legal and administrative challenges for previously issued MDOs. Expect this to be a significant stream of vaping industry news in the near future. After some debate, Congress passed in March 2022 and the president signed a bill updating the Tobacco Control Act, which states that nicotine-containing products of any kind can be regulated by the FDA`s Tobacco Products Center and sets a timeline for doing so. Manufacturers of e-cigarettes and other nicotine products have used synthetic nicotine to exploit a regulatory loophole and continue to sell the types of sweetened and fruity flavoured products that triggered the youth vaping epidemic that continues to this day. Fortunately, this loophole is closing. Although most nicotine products on the market use tobacco or tobacco-derived nicotine to create and facilitate addiction, synthetic nicotine products have gained new attention and notoriety in recent years. Historically, synthetic nicotine tended to produce nicotine that was not as bioavailable as tobacco-derived nicotine.
(The bioavailability of a drug refers to its ability to be absorbed and used by the body and, in the case of nicotine, its addictive potential.) As early as the 1960s, the tobacco industry was looking for methods of producing and using synthetic nicotine (and other nicotine analogues), but internal documents show that the industry eventually concluded that the cost of producing nicotine as bioavailable as tobacco-derived nicotine would be much higher than simply deriveling nicotine directly from tobacco.
